Healthcare Industry News: immunodeficiency
News Release - August 8, 2007
Calypte Appoints J. Daniel Clark as Vice President Sales and Marketing
LAKE OSWEGO, Ore.--(HSMN NewsFeed)--Calypte Biomedical Corporation (OTCBB: CBMC ), a manufacturer of medical diagnostic tests for the rapid detection of antibodies to the human immunodeficiency virus (HIV), announced today that J. Daniel Clark has been appointed Vice President Sales and Marketing. Mr. Clark's background includes over 35 years in general management and sales and marketing in the health care industry, with an emphasis on technology licensing and international distribution. For the past seven years Mr. Clark has been a consultant to the medical device industry with an international focus, including recent assignments in China."I am pleased that we were able to attract such an experienced and accomplished sales executive as Dan," said Roger I. Gale, Calypte's Chairman and Chief Executive Officer. "As we transition into a sales-driven company, Dan's experience and relationships, particularly in China and the international markets should prove invaluable. His ability to establish and manage an international distribution network will support our current activities and help us enter new markets. We believe he is a perfect fit to help us in the next phase of our Company's growth."
Prior to consulting to the medical device industry, Mr. Clark was the co-founder, Chairman and CEO of MagneVu, a private medical device company, where he guided the company through its start up period and the FDA approval process, and established a product that later would be marketed by GE Medical Systems. Prior to MagneVu, Mr. Clark held several CEO and senior management positions within the medical device industry, including a 12-year career with Johnson & Johnson's Technicare division, where he was U.S. Corporate Vice President of Customer Relations.
While at Johnson & Johnson Mr. Clark's extensive International experience included overseas sales and operational assignments with responsibility for Pacific Rim countries including Japan, Korea, Indonesia, Malaysia, Taiwan, Hong Kong, Singapore and the Philippines, as well as countries in Europe, Eastern Europe, the Middle East and Africa. He began his career as a sales representative for Becton, Dickenson & Co. Mr. Clark holds a Bachelor of Science and a Master of Arts degree in communications from Eastern New Mexico University.
Mr. Clark commented, "I expect to be able to make an immediate impact by establishing a sales distribution organization. With larger company and extensive international hands-on experience, as well as several years as CEO of companies similar to Calypte, I look forward to working with Roger and the management team at this point in the Company's evolution. Calypte has proven products at the beginning of their growth cycle and an anticipated pipeline of complementary products to follow. I am pleased to join Calypte at this time and help accelerate its growth curve."
About Calypte Biomedical:
Calypte Biomedical Corporation (www.calypte.com) is a U.S.-based healthcare company focused on the development and commercialization of rapid testing products for sexually transmitted diseases such as the AwareTM HIV-1/2 OMT test that are suitable for use at the point of care and at home. Calypte believes there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in developing countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other sexually transmitted infectious diseases may make important contributions to public health, and could increase the likelihood of treating those with undetected HIV and other sexually transmitted diseases.
Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company's ability to obtain additional financing, if and as needed, and access funds from its existing financing arrangements that will allow it to continue its current and future operations and whether demand for its test products in domestic and international markets will generate sufficient revenues to achieve positive cash flow and profitability. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-KSB for the year ended December 31, 2006 and its subsequent filings with the SEC.
Source: Calypte Biomedical
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!